Non-Small Cell Lung Cancer (NSCLC)

The safety profile of durvalumab plus chemoradiation among patients with unresectable non–small cell lung cancer in the phase 3 PACIFIC-2 trial appears to be consistent with prior reports.

A medical oncologist reviews intracranial efficacy data from HERTHENA-Lung01 on patritumab deruxtecan (HER3-DXd) in patients with previously treated advanced EGFR-mutated NSCLC.

Alexander I. Spira, MD, PhD, FACP, reviews recent data from MARIPOSA-2 looking at amivantamab plus chemotherapy, with or without lazertinib, in EGFR-mutated advanced NSCLC.

Cell therapy and vaccine approaches are among the several potential options for targeting KRAS in patients with KRAS G12C–mutated non–small cell lung cancer, says Sandip P. Patel, MD.

Data from the phase 3 MARIPOSA-2 study support the supplemental biologics license application for amivantamab plus chemotherapy in EGFR-mutated advanced or metastatic non–small cell lung cancer.

Data from the phase 1/2 TRIDENT-1 trial support the FDA approval of repotrectinib for those with ROS1-positive advanced or metastatic non–small cell lung cancer.

Adagrasib, which now has a positive CHMP opinion, was previously examined as part of the phase 1/2 KRYSTAL-1 study.

Next steps for research in lung cancer may include identifying how the gut microbiome impacts responses and adverse effects associated with treatment, says Misako Nagasaka, MD, PhD.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discussed how to best mitigate adverse effects in patients with non–small cell lung cancer.

Results from the phase 2 THIO-101 trial demonstrate disease control in all 19 patients with non–small cell lung cancer who received second-line THIO plus cemiplimab.

Investigators of the phase 3 KEYNOTE-671 trial identify no new safety signals with pembrolizumab plus chemotherapy in those with early-stage non–small cell lung cancer.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.

Amivantamab plus chemotherapy may be the new standard of care for patients with EGFR-mutated advanced non–small cell lung cancer that has progressed following osimertinib, according to Antonio Passaro, MD, PhD.

Objective response rate appears to be higher with datopotamab deruxtecan compared with docetaxel among patients with advanced or metastatic non–small cell lung cancer in the phase 3 TROPION-Lung01 study.

Amivantamab plus lazertinib may represent a new standard of care in those with EGFR-mutated advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Misako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, discuss the importance of early dermatological consultations and multidisciplinary education for managing infusion-related adverse events like rashes from amivantamab, emphasizing the benefits of a well-coordinated team and the value of experience in responding to reactions.

Kristen Neumann, DNP, FNP-C, emphasizes the efficacy of the drug amivantamab for patients with EGFR exon 20 mutations, explaining the challenges of unique skin rashes, but highlighting the importance of teamwork in effectively managing and treating these adverse skin effects.

Amivantimab produces superior progression-free survival in EGFR exon 20 insertion–positive non–small-cell lung cancer.

Patients with RET fusion–positive non–small cell lung cancer experienced improved progression-free survival with first-line selpercatinib.

Alectinib improves disease-free survival in patients with ALK-positive non–small-cell lung cancer.

Central nervous system progression was reduced with osimertinib plus chemotherapy for patients with EGFR-mutated non-small cell lung cancer plus CNS metastases.

Neoadjuvant nivolumab combination followed by surgery and adjuvant nivolumab show an improvement in event-free survival for patients with previously untreated resectable stage II to IIIB non-small cell lung cancer.

Results from the phase 2 PERLA trial showed an improved objective response and overall survival in treatment with dostarlimab plus chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer.

Data from the phase 2 KRYSTAL-7 study support a phase 3 trial assessing concurrent adagrasib plus pembrolizumab compared with pembrolizumab alone in treatment-naïve KRAS G12C-mutated non–small cell lung cancer.